Clinical studies on antihypertensive drugs used for proteinuria and hypertension intended for the bevacizumab-treated patients
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000034880
- Lead Sponsor
- Iwate Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have continued therapy with bevacizumab for more than 3 months 2) Patients who show proteinuria at least once within 4 weeks before consent acquisition 3) Patients with renal dysfunction of eGFR less than 30 mL / min / 1.73 m 2 at the time of consent acquisition 4) Patients who have taken the following medications before consent acquisition: ARB, angiotensin II converting enzyme inhibitor, direct renin inhibitor, diuretic, CCB, alpha / beta antagonist 5) Patients with diabetes 6) Patients with cardiovascular disorders 7) Patients who may be pregnant or pregnant 8) Patients who are considered difficult to register in this study due to clinically problematic mental illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method